Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$297.2MCash on Hand
30.3mo Cash Runway
Follow AURA by emailGet an email when AURA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AURA, unsubscribe in one click. Privacy
📣 What AURA Says Is Next
2H 2027 · “Clinical Pipeline Across Ocular Oncology Program Preclinical Phase 1 Phase 2 Phase 3 Early Choroidal Melanoma Metastases tothe Choroid Cancers of theOcular Surface Topline data from the 15-month primary endpoint remain on track for 2H 2027 MoA, mechanism of action; VLP, virus-like particle.”
Company press release, Nov 9, 2026 · SEC filing
second half of 2027 · “The trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027.”
Company press release, Nov 9, 2026 · SEC filing
2H 2027 · “Clinical Pipeline Across Ocular Oncology Program Preclinical Phase 1 Phase 2 Phase 3 Early Choroidal melanoma Metastases tothe Choroid Cancers of theOcular Surface Topline data from the 15-month primary endpoint remain on track for 2H 2027 DLT, dose-limiting toxicity; MoA, mechanism of action; NMIBC, non-muscle-invasive bladder cancer; SAE, serious adverse event; VLP, virus-like particle.”
Company press release, Aug 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q3 2026 results: cash and equivalents of $297.2 million, enough to fund operations into 1H 2029. Phase 3 CoMpass trial enrollment complete with 108 participants, topline data expected 2H 2027. Net loss $32.1 million, including $4.5 million in restructuring charges. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
Restructuring Reported Q2 2026 results and announced a roughly 20% workforce reduction and a shift in focus to ocular oncology, deprioritizing its NMIBC program, with estimated restructuring costs of $2.9 million to $3.2 million. Expects cash runway into 1H 2029. Form 8-K · SEC filing · Press release
Aug 11, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 11, 2026 ·
Financing Aura Biosciences filed a shelf registration statement to sell up to $500,000,000 of common stock, preferred stock, debt securities, warrants and/or units from time to time. Up to $200,000,000 of common stock may be sold through an open market sale agreement with Jefferies LLC. Shares closed at $7.70 on August 10, 2026. Form S-3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Nov 2026 · Phase 2 · Recruiting · Suprachoroidal Administration in Subjects With Metastases to the Choroid Registry primary completion date, not a results date
Mar 2027 · Phase 1 · Active Trial · A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Registry primary completion date, not a results date
Nov 2027 · Phase 3 · Active Trial · A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or… Registry primary completion date, not a results date
Aug 2028 · N/A · Active Trial · Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects Registry primary completion date, not a results date
Dec 2028 · N/A · Active Trial · A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AURA holds $297.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $29.5M/quarter from operations,
an estimated runway of 30.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:30 · Moderate
Cash runway 30 months
ATM program on file since Aug 2026 +15
Shelf registration (S-3, Aug 2026) +10
Company says cash lasts into the first half of 2029 -15We believe that our existing cash and cash equivalents and marketable securities will enable us to fund our operations into the first half of 2029.10-Q, Nov 2026
Share count +64% in a year +20
Recent financing filings on SEC EDGAR:
Aug 11, 2026 · Shelf registration with ATM program, up to $200M · S-3
Share count 104,074,302 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AURA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AURA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.